Clinuvel Pharmaceuticals saw its stock price rise 60% after the FDA approved its drug SCENESSE for the treatment of erythropoietic protoporphyria (EPP). SCENESSE works by darkening the skin through a tanning-like process to protect against the sunlight sensitivity experienced by EPP patients. SCENESSE is already approved in Europe for treating porphyria and is available in Germany, Austria, the Netherlands, Italy and Switzerland, but some countries still ban its use. An estimated 45 million patients worldwide could benefit from SCENESSE.